PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Screening programs”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 973 records · Page 54Linked to original sources
PubMed1993

Satisfaction of attenders during the establishment of an Australian mammography screening program.

We aimed to examine the satisfaction and the predictors of reported satisfaction with the service offered by a pilot mammography screening service. Information was collected from 481 attenders at the screening clinic and from 318 consecutive attenders at the recall clinic using two different standard self-administered questionnaires covering respectively six and five dimensions of satisfaction. For the screening clinic attenders, mean scores on most subscales indicated quite high levels of satisfaction. There were no significant differences among different samples over time for the perceptions of technical competence of the staff. Decreases in reported level of satisfaction were found for subscales measuring interpersonal skills, information giving, physical surroundings, convenience and accessibility, and general satisfaction. Waiting times, age and marital status were predictors in most satisfaction subscales. For those attending the recall clinic, mean satisfaction scores for most scales were high, except for the scale measuring satisfaction with the way the results were received. The median time between screening and recall visits for women in this study was 27 days (range 3 to 112 days). Attenders were most dissatisfied with the delay in getting results, an area where the service might improve.

Aged↗
PubMed1997

NCI's anticancer drug screening program may not be selecting for clinically active compounds.

To discover new anticancer drugs the U.S. National Cancer Institute (NCI) currently screens roughly 10,000 compounds annually against a panel of 60 human tumor cell lines. Drug activity is determined using a 2-day growth inhibition assay with the cells maintained in contact with the drugs for the 2-day period. Analyses of the more than 60,000 compounds screened to date against this panel of cell lines have revealed surprisingly detailed correlations between drug activities and the molecular genotypes and phenotypes of the cells. For example, most of the drugs, particularly those active in the clinic, are most active against p53 wild-type cells. This commentary points out, however, that these patterns of activity, and by implication the compounds identified as active, may not be relevant to tumor response in vivo. This is because tumor response is determined by tumor cell kill, and there is no reason to suppose that drug-induced short-term growth inhibition should correlate with drug-induced cell kill, usually measured by the ability of the cell to divide indefinitely to form a colony. We have tested a subset of the panel of NCI cell lines for cell kill by clonogenic assay using cisplatin and mitomycin C and have found only a weak and nonsignificant correlation between cell kill and activity determined by the NCI using the growth inhibition assay. It is concluded that a more extensive comparison of the 2-day growth inhibition and clonogenic assays should be made, as well as a test of which is more relevant to the response of human tumor xenografts.

Animals↗